Announced details
Ranked first in monthly outpatient prescription sales in South Korea in April 2026, ranking first among 10,476 products surveyed.
Cumulative domestic sales in South Korea through 2025 (outpatient prescription sales): KRW 923.3 billion. Sold in 20 countries.
The Company licensed tegoprazan to HK inno.N. Under the licensing agreement, the Company holds the right to receive a portion of the revenue that HK inno.N receives from its partners.
Head office: Osong, South Korea. Other company details: Not disclosed.
The Company believes this will contribute to enhancing the corporate value of its group over the medium to long term. The specific impact on financial results: Not disclosed.
The company does not address Contract Value / Offering price.
Data from a pharmaceutical market research firm and official announcements by HK inno.N
| Item | Details |
|---|---|
| Names of Products / Services Covered | tegoprazan, K-CAB® |
| Counterparty | HK inno.N Corporation (HK inno.N) |
| Counterparty overview | Head office: Osong, South Korea. Other company details: Not disclosed. |
| Relationship with the Company | The Company licensed tegoprazan to HK inno.N. Under the licensing agreement, the Company holds the right to receive a portion of the revenue that HK inno.N receives from its partners. |
| Launch date | March 2019 (launch in South Korea; track record) |
| Applicable area | Erosive gastroesophageal reflux disease (EE), Non-erosive gastroesophageal reflux disease (NERD), Gastric ulcers, Helicobacter pylori eradication therapy, Maintenance therapy, Prevention of NSAID-induced ulcers |
| Quantitative Effects | Ranked first in monthly outpatient prescription sales in South Korea in April 2026, ranking first among 10,476 products surveyed. |
| Usage history | Cumulative domestic sales in South Korea through 2025 (outpatient prescription sales): KRW 923.3 billion. Sold in 20 countries. |
| Impact on Business Performance | The Company believes this will contribute to enhancing the corporate value of its group over the medium to long term. The specific impact on financial results: Not disclosed. |
| Source | Data from a pharmaceutical market research firm and official announcements by HK inno.N |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The factors cited as underlying the growth include efficacy and safety demonstrated by accumulated clinical data, the securing of a broad range of indications, and the establishment of trust among healthcare professionals.